What Is the Shattuck Labs, Inc. (STTK) Class Action Lawsuit About?

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. (“Shattuck” or “the Company”) (NASDAQ: STTK). Investors who purchased Shattuck securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Shattuck has violated federal securities laws.

Investigation Details

On October 1, 2024, Shattuck issued a press release announcing the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage data.  Specifically, Shattuck’s decision came after an interim Phase 1 readout indicated that SL-172154, compared to azacitidine monotherapy, failed to improve median overall survival in certain patients with myeloid leukemia and myelodysplastic syndromes in combination with azacitidine.  On this news, Shattuck’s stock price fell $1.57 per share, or 44.99%, to close at $1.92 per share on October 1, 2024.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Shattuck securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.